- On track to report preliminary data from Phase 1 monotherapy expansion cohorts of MICVO for 2L/3L R/M HNSCC patients who have received prior platinum-based chemotherapy and prior PD-(L)1 inhibitor therapy in second half of 2025, and 2L/3L R/M HNSCC patients who have received prior EGFRi and PD-1 inhibitor therapy in first half of 2026 - On track to report preliminary data from Phase 1 trial of MICVO in combination with pembrolizumab targeting multiple tumor types including 1L/2L HNSCC patients in second h ...

(All figures are in Canadian dollars, unless stated otherwise. Average exchange rate in Q1 2025: C$1.00 = R$3.93) SINGAPORE, May 15, 2025 (GLOBE NEWSWIRE) -- Verde AgriTech Ltd (TSX: "NPK") ("Verde" or the "Company") announces its financial results for the period ended March 31, 2025 ("Q1 2025"). As previously disclosed on March 28, 2025, product deliveries for the first half of 2025 were significantly impacted by the severe crisis in the Brazilian agricultural sector, which led to the insolvency of some of ...

VANCOUVER, British Columbia, May 15, 2025 (GLOBE NEWSWIRE) -- Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) ("Rubicon Organics" or the "Company"), a licensed producer focused on cultivating and selling organic certified and premium cannabis products, today announced the appointment of Glen Ibbott, a cannabis industry veteran and former Chief Financial Officer of Aurora Cannabis Inc. (TSX: ACB, Nasdaq: ACB) as its Interim Chief Financial Officer. Janis Risbin, current CFO, will be stepping away from her ...

Mr. Stachowiak continued, "We are very pleased with our successful acquisition of the Rhode Island radiation therapy treatment centers and the opening of our Puebla, Mexico facility. We are looking forward to further long-term growth from the new Esprit installed in Guadalajara, Mexico that is expected to startup in late 2025 and from our recent Certificate of Need approvals for the first radiation therapy treatment center in Bristol, Rhode Island and a proton beam radiation therapy treatment center in John ...

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Marex Group plc ('Marex' or the 'Group'; Nasdaq: MRX) a diversified global financial services platform, providing essential liquidity, market access and infrastructure services to clients in the energy, commodities and financial markets, today reported financial results for the first quarter ('Q1 2025'). Ian Lowitt, Group Chief Executive Officer, stated, "Robust levels of client activity across our businesses and positive market conditions led to a strong performan ...

Reykjavík, May 15, 2025 (GLOBE NEWSWIRE) -- ("Amaroq Minerals" or the "Company") TORONTO, ONTARIO – May 15, 2025 – Amaroq Minerals Ltd. (AIM, TSXV, NASDAQ Iceland: AMRQ), an independent mining company with a substantial land package of gold and strategic mineral assets in Southern Greenland, announces that it has posted its Annual Report and Financial Statements for the year ended December 31, 2024 and Notice of Annual and Special General Meeting of Shareholders ("Meeting") and Management Information Circul ...

LEXINGTON, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced the first peer-reviewed publication of data demonstrating the ability of alkaline phosphatase (ALPL) to transport a novel AAV capsid across the blood-brain barrier (BBB). The article, titled "Highly conserved brain vascular receptor ALPL mediates transport of engineered AAV vectors across the blood-brain barrier ...

Before Marex's initial public offering (IPO) on Nasdaq in April 2024, private equity shareholders including JRJ Group held around 96% of Marex stock. Following the IPO and two successful secondary follow-on offerings, private equity owners now hold around 30% of Marex stock. LONDON, May 15, 2025 (GLOBE NEWSWIRE) -- Marex Group Plc (NASDAQ: MRX), the diversified global financial services platform, announces today that Roger Nagioff has stepped down from the Group Board. Roger represented private equity inves ...

CAMBRIDGE, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the first quarter ended March 31, 2025. "Given recent positive front-line data reported from topo-1 ADC registrational trials, we believe the post-topo-1 breast cancer patient populati ...

PITTSBURGH, May 15, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science- driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended March 31, 2025, and provided a corporate update. The Company reported a loss from continuing operations of approximately ...